• 대한상한금궤의학회지
• /
• v.6 no.1
• /
• pp.89-96
• /
• 2014

Objective : This case report evaluated the effect of Soseungki-tang(小承氣湯) on mood disorder. Methods : A patient of mood disorder was treated with Soseungki-tang(小承氣湯) in accordance with Shanghanlun(傷寒論) six meridian patterns diagnostic system. Results : After a series of Soseungki-tang treatment, the symptoms of mood disorder patient improved. Conclusions : According to Shanghanlun(傷寒論) six meridian patterns diagnostic system, this case study shows that Soseungki-tang is effective on mood disorder. However further clinical studies in depth are needed.

• Korean Journal of Biological Psychiatry
• /
• v.9 no.1
• /
• pp.3-7
• /
• 2002

Genes involved in the serotonin system are good candidates for the pathogenesis of mood disorder and mood-related disorders, such as eating disorder, obsessive-compulsive disorder, alcoholism, and suicide. Serotonin type 2A(5-HT2A) receptor gene promoter polymorphism(-1438A/G) has been reported. In this article, authors reviewed the literatures regarding association studies between -1438A/G and mood disorder and mood-related disorders. There are controversial results with limited data to date. Further researches on the -1438A/G in psychiatric disorders are required.

• Clinical Psychopharmacology and Neuroscience
• /
• v.20 no.2
• /
• pp.228-239
• /
• 2022

Bipolar disorder is a mental illness that causes extreme mood swings and has a chronic course. However, the mechanism by which mood episodes with completely opposite characteristics appear repeatedly, or a mixture of symptoms appears, in patients with bipolar disorder remains unknown. Therefore, mood stabilizers are indicated only for single mood episodes, such as manic episodes and depressive episodes, and no true mood-stabilizing drugs effective for treating both manic and depressive episodes currently exist. Therefore, in this review, therapeutic targets that facilitate the development of mood stabilizers were examined by reviewing the current understanding of the neuromolecular etiology of bipolar disorder.

• Korean Journal of Biological Psychiatry
• /
• v.27 no.2
• /
• pp.74-83
• /
• 2020

Objectives Psychological resilience plays a significant role in many aspects of mental health. The aim of this study was to find an association between childhood attention deficit hyperactivity disorder (ADHD) features and adulthood psychological resilience in patients with mood disorders. Methods A total of 213 patients with mood disorders including major depressive disorder or bipolar I, II disorder and 909 healthy controls were included. We assessed childhood ADHD features using the Wender Utah Rating Scale (WURS), adulthood psychological resilience using the Connor-Davidson Resilience Scale (CD-RISC), and current depressive mood using the Beck Depression Inventory (BDI). Pearson's correlation, multiple linear regression and a mediation analyses were performed to examine the relationships between three WURS factor (impulsivity, inattention, and mood instability) scores, the BDI score, and the CD-RISC score. Results The CD-RISC score was negatively correlated with the WURS childhood inattention factor score and current BDI score in patients with mood disorders. BDI score mediated the influence of the inattention factor score on CD-RISC score among patients with mood disorders. The CD-RISC score was significantly lower in patients with mood disorders than in controls even after controlling for age, WURS scores, and the BDI score. Conclusions An evaluation of psychological resilience is important for enhancing recovery and quality of life in patients with mood disorders. When assessing psychological resilience, current depression and ADHD features in childhood, particularly inattention, should be considered.

• Korean Journal of Biological Psychiatry
• /
• v.5 no.2
• /
• pp.155-161
• /
• 1998

Mood disorder is a medical illness resulting from the disorder of CNS neurotransmission and its principal therapeutic tool is pharmacotherapy. Psychotherapeutic drugs for mood disorder have some clinical limitations which are due to no or partial response, decreased compliance for drug by the side effects, and delayed therapeutic effects. So, general hope of all clinicians that mood diorder will respond to a single psychotherapeutic agent may be the exception rather than the rule. Recently, combined drug treatments have become increasingly popular to overcome the clinical limitations of individual agent in mood disorder. Combined treatments are usually used for augmenting or initiating rapidly the effect of drug, and for treating different target symptoms or drug side effects. When combined treatments being tried, knowledge of the action mechanism, pharmacokinetics, and pharmacodynamics is crucial to cope with the possible adverse reactions of drugs.

• Korean Journal of Biological Psychiatry
• /
• v.18 no.1
• /
• pp.15-24
• /
• 2011

Mood disorder is unlikely to be a disease of a single brain region or a neurotransmitter system. Rather, it is now generally viewed as a multidimensional disorder that affects many neural pathways. Growing neuroimaging evidence suggests the anterior cingulate-pallidostriatal-thalamic-amygdala circuit as a putative cortico-limbic mood regulating circuit that may be dysfunctional in mood disorders. Brain-imaging techniques have shown increased activation of mood-generating limbic areas and decreased activation of cortical areas in major depressive disorder(MDD). Furthermore, the combination of functional abnormalities in limbic subcortical neural regions implicated in emotion processing together with functional abnormalities of prefrontal cortical neural regions probably result in the emotional lability and impaired ability to regulate emotion in bipolar disorder. Here we review the biological correlates of MDD and bipolar disorder as evidenced by neuroimaging paradigms, and interpret these data from the perspective of endophenotype. Despite possible limitations, we believe that the integration of neuroimaging research findings will significantly advance our understanding of affective neuroscience and provide novel insights into mood disorders.

• Journal of the Korean society of biological therapies in psychiatry
• /
• v.24 no.3
• /
• pp.194-201
• /
• 2018

Objectives : Some studies have reported that chronotypes, among several factors, could contribute to problematic drinking. However, there is little evidence confirming this relationship between chronotype and problematic drinking based on gender differences in mood disorder. This study is to investigate the difference of the relationship between chronotype and problematic drinking according to gender differences in mood disorder. Methods : Two hundred fifteen patients with mood disorder were recruited. Problematic drinking and chronotypes were assessed by the Alcohol Use Disorder Identification Test in Korea(AUDIT) and the Korean translation of composite scale of morningness(KtCS). We analyzed the correlation between KtCS and AUDIT using Pearson's correlation, and compared AUDIT scores according to chronotypes classified by KtCS between male and female patients using analysis of variance(ANOVA). Results : There was no significant difference in AUDIT scores between the male and female patients(t=0.91, p=0.183). In female patients, eveningness had significantly higher AUDIT scores than other chronotypes(F=0.199, p=0.033). Meanwhile, in male patients, there was no significant difference in AUDIT score among chronotypes(F=0.008, p=0.933). Conclusion : This study suggests that eveningness might be associated with problematic drinking in female patients who suffer from mood disorder. It also suggests that chronotherapeutical treatment might be able to help improve the course in female patients with mood disorder. In the future, a large-scale prospective study is needed to confirm these results.

• Korean Journal of Psychosomatic Medicine
• /
• v.22 no.2
• /
• pp.63-70
• /
• 2014

The prevalence of obesity and overweight is increasing in mood disorder, and it is connected to an increased cardiovascular mortality. Because of them, treatment for obesity may be an essential part of mood disorder treatment. Similar to the general population, non-pharmacological treatment such as correction of life habits should be considered first of all. If this approaches are fail, pharmacological treatment for obesity would be required as next step. Any drug for obesity is not approved officially in mood disorder. So approved drugs in general population, and drugs supported by several studies are prescribed in clinical settings. Several treatment guidelines for mood disorder and studies support that orlistat, metformin, topiramate and bupropion is effective and safe.

• Anxiety and mood
• /
• v.6 no.1
• /
• pp.10-16
• /
• 2010

Researchers consider obsessive-compulsive disorder (OCD) to be an anxiety disorder, but it often shows comorbidity with other disorders in the affective spectrum. Epidemiological and clinical studies have shown a strong association between OCD and mood disorders. In addition, some reports show the patients with OCD have attentional-processing impairments regarding emotional information. However, research has not revealed the exact nature and degree to which OCD constitutes an affective problem. In this review, we discuss the affective aspects of OCD and the relationship between OCD and mood disorders.

• Korean Journal of Biological Psychiatry
• /
• v.4 no.2
• /
• pp.198-210
• /
• 1997

To examine the double-faced thymoleptic(antidepressant and antimanic) effects of risperidone in mood disorders, this article reviews the psychotropic-induced mania, thymoleptic effects of antipsychotics, therapeutic effects of risperidone and risperidone(RIS)-induced mania(RIM) in mood disorders, risk factors of RIM, possible neurochemical mechanism of these thymoleptic effects, pathophysiological and clinical significance of thymoleptic effects, and suggestive clinical guideline of RIS in mood disorders. RIS appeared effective for bipolar disorder at a lower dose than that recommended for schizophrenia, especially in the cases of maintenance of mood stabilizers, and gradual titration from low doses. Manic induction/exacerbation can occur by chance during RIS treatment in mood disorders, schizoaffective disorders, and schizophrenias. The possible risk factors for RIM are refractory mood disorder, especially in bipolar I disorder with poor initial response ; refractory schizoaffective disorders, especially in bipolar type with poor initial response ; refractory chronic schizophrenias, especially with initial responses ; psychotic features ; higher initial doses ; rapid titration ; combined therapy with antidepressants in refractory depression ; and RIS monotherapy in mania/hypomania. RIS is a drug that preferentially block 5-HT2 receptors. The effects of low dose are due mainly to the blockade of 5-HT2 receptors. There are more gradual increase in D2 blockade with increasing dose and this D2 blocking properties become apparent at higher doses. This may be related to a modulation of dopaminergic transmission by 5-HT2 antagonism at lower doses with the direct action of RIS on DA receptors coming into play at higher dose. The serotonergic antagonistic effect may be important for its effects on depressive symptoms. This, together with adequate blo-ckade of D2 receptors, may not necessarily lead to destabilization of mood disorder, but rather to more therapeutic effects. Therefore, this dose-receptor affinity relationship with both antidepressant and antimanic effects according to treatment duration can explain a continuum of antidepressant effect, antimanic effect, behavioral stimulation, and manic/hypomanic induction/exacerbation. It was the recognition of a useful psychiatric side effects by a thoughtful observer with fertile minds that led to their ultimate utilization as psychotropic drugs, i.e., phenothiazine, MAOI, TCA, and lithium. And, in vivo pharmacological challenge by novel psychotropics, as a neurochemical probe, with more specific actions is a useful tool to select pharmacologically homogeneous subgroup of the same phenotypical(clinical) condition, to further study the unknown underlying pathogenesis of various mental illnesses. Finally, RIS may be a useful alternative or adjunctive drug for patients with mood disorders without psychotic features or refractory to treatment with standard antipsychotic drugs. The more conservative doses(tirated slowly from 1-3 mg/d) of RIS, and maintenance of mood stabilizer in the cases with risk factors of RIM are recommended in mood disorder.